Extract ALL safety data from this case report/series about {{ drug_name }}.

DRUG: {{ drug_name }}
IDENTIFIED SAFETY TABLES: {{ safety_tables }}

PAPER CONTENT:
{{ paper_content }}

Extract EVERY adverse event and safety outcome mentioned:
- Any adverse events (AEs)
- Serious adverse events (SAEs)
- Adverse events of special interest
- Laboratory abnormalities
- Treatment discontinuations
- Dose modifications

For each safety event, extract:
{
    "event_name": "name of the adverse event",
    "event_category": "AE" or "SAE" or "AESI" or "Discontinuation" or "Lab abnormality",
    "category_soc": "Infections | Malignancies | Cardiovascular | Thromboembolic | Hepatotoxicity | Cytopenias | GI Perforation | Hypersensitivity | Neurological | Pulmonary | Renal | Death | Metabolic",
    "infection_type": "Bacterial | Viral | Fungal | Mycobacterial | Opportunistic | Herpes Zoster" or null (only for infections),
    "malignancy_type": "Hematologic | Solid Tumor | NMSC" or null (only for malignancies),
    "cv_type": "MACE | Heart Failure | Arrhythmia" or null (only for cardiovascular),
    "thromboembolic_type": "VTE | DVT | PE | Arterial" or null (only for thromboembolic),
    "is_class_effect": true/false (is this a known effect for this drug class?),
    "severity_grade": "Grade 1-5 or Mild/Moderate/Severe" or null,
    "patients_affected_n": number of patients or null,
    "patients_affected_pct": percentage or null,
    "events_total": total event count or null,
    "relatedness": "Related" or "Possibly related" or "Unrelated" or null,
    "outcome": "Resolved" or "Ongoing" or "Fatal" or null,
    "action_taken": "Dose reduced" or "Discontinued" or "None" or null,
    "notes": "additional context"
}

CATEGORY CLASSIFICATION GUIDE (category_soc):
- Infections: Any infection including URI, UTI, pneumonia, sepsis, opportunistic infections, TB, herpes zoster
- Malignancies: Any cancer diagnosis, lymphoma, leukemia, solid tumors, NMSC
- Cardiovascular: MI, stroke, cardiovascular death, heart failure, arrhythmias
- Thromboembolic: DVT, PE, arterial thrombosis, portal vein thrombosis
- Hepatotoxicity: Elevated transaminases, hepatitis, liver failure, drug-induced liver injury
- Cytopenias: Anemia, neutropenia, thrombocytopenia, pancytopenia, lymphopenia
- GI Perforation: Bowel perforation, GI perforation (especially relevant for JAK inhibitors)
- Hypersensitivity: Anaphylaxis, angioedema, severe allergic reactions, drug hypersensitivity
- Neurological: Headache, neuropathy, demyelination, seizures
- Pulmonary: ILD, pneumonitis, respiratory failure (non-infectious)
- Renal: AKI, creatinine elevation, renal failure
- Death: Any death, include cause if known
- Metabolic: Lipid changes, CPK elevation, weight gain

KNOWN CLASS EFFECTS (for is_class_effect):
- JAK inhibitors: Herpes zoster, VTE, MACE, malignancies, cytopenias, lipid elevations
- IL-1 inhibitors: Injection site reactions, infections
- Anti-CD20: Infusion reactions, infections, hypogammaglobulinemia
- TNF inhibitors: Infections, TB reactivation, demyelination, heart failure

Return JSON array of ALL safety events found:
[
    {event 1},
    {event 2},
    ...
]

Include ALL adverse events mentioned.

{% include 'case_series/_partials/json_rules.j2' %}

